NASDAQ:FNCH Finch Therapeutics Group (FNCH) Stock Forecast, Price & News $5.10 -0.21 (-3.95%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$4.95▼$5.2950-Day Range$5.10▼$8.9052-Week Range$4.95▼$60.00Volume5,650 shsAverage Volume17,280 shsMarket Capitalization$8.16 millionP/E RatioN/ADividend YieldN/APrice Target$210.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Finch Therapeutics Group MarketRank™ ForecastAnalyst Rating0.00 Rating ScoreUpside/Downside4,017.6% Upside$210.00 Price TargetShort InterestBearish5.05% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($30.98) to ($20.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.56 out of 5 stars 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $210.00, Finch Therapeutics Group has a forecasted upside of 4,017.6% from its current price of $5.10.Amount of Analyst CoverageFinch Therapeutics Group has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.05% of the float of Finch Therapeutics Group has been sold short.Short Interest Ratio / Days to CoverFinch Therapeutics Group has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Finch Therapeutics Group has recently increased by 27.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldFinch Therapeutics Group does not currently pay a dividend.Dividend GrowthFinch Therapeutics Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FNCH. Previous Next 1.9 News and Social Media Coverage News SentimentFinch Therapeutics Group has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Finch Therapeutics Group this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for FNCH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Finch Therapeutics Group insiders have not sold or bought any company stock.Percentage Held by Insiders44.90% of the stock of Finch Therapeutics Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.43% of the stock of Finch Therapeutics Group is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Finch Therapeutics Group are expected to grow in the coming year, from ($30.98) to ($20.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Finch Therapeutics Group is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Finch Therapeutics Group is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFinch Therapeutics Group has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Finch Therapeutics Group (NASDAQ:FNCH) StockFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.Read More FNCH Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FNCH Stock News HeadlinesSeptember 19, 2023 | americanbankingnews.comFinch Therapeutics Group (NASDAQ:FNCH) Stock Price Down 2.6%August 21, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Nuvation Bio (NUVB), Finch Therapeutics Group (FNCH)September 29, 2023 | Behind the Markets (Ad)New Breakthrough "Living Software" Has Been…New Breakthrough "Living Software" Has Been... Ukraine's "Secret Weapon" Against Russia The Washington Post Reports: "It's a big reason David is beating Goliath..." The Wall Street Journal Reports: "it's a technical revolution." Jeff Bezos Said: "It's in the realm of science fiction." Early investors can reap 5,633% gains on the small company revolutionizing warfare >>>June 9, 2023 | finanznachrichten.deFinch Therapeutics Group, Inc.: Finch Announces Reverse Stock Split of Common StockMay 13, 2023 | msn.comHC Wainwright & Co. Reiterates Finch Therapeutics Group (FNCH) Buy RecommendationMay 12, 2023 | marketwatch.com8-K: Finch Therapeutics Group, Inc.May 10, 2023 | finanznachrichten.deFinch Therapeutics Group, Inc.: Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdatesMay 10, 2023 | finance.yahoo.comFinch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdatesSeptember 29, 2023 | Stansberry Research (Ad)Bank Collapse Causes Gold Prices to SoarSilicon Valley Bank was the second-largest bank in American history to fail, and investors have started piling into the safety and security of gold. But if you're not taking advantage of a little-known way to invest for around $5 today, you're missing out.April 25, 2023 | finance.yahoo.comFinch Therapeutics Announces Executive Leadership TransitionsApril 22, 2023 | finanznachrichten.deFINCH THERAPEUTICS GROUP INCApril 18, 2023 | finance.yahoo.comFinch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License AgreementApril 4, 2023 | markets.businessinsider.comFinch Therapeutics Group (FNCH) Gets a Buy from H.C. WainwrightApril 3, 2023 | finanznachrichten.deFinch Therapeutics Group, Inc.: Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesMarch 25, 2023 | msn.comLooking Into Finch Therapeutics Group's Return On Capital EmployedMarch 25, 2023 | finance.yahoo.comFinch Therapeutics Group Full Year 2022 Earnings: Misses ExpectationsMarch 23, 2023 | finance.yahoo.comFinch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesJanuary 24, 2023 | finance.yahoo.comMicrobiome startup cuts 95% of remaining staff in 3rd layoff in 9 monthsJanuary 24, 2023 | marketwatch.comFinch Therapeutics Ending Phase 3 Study, Cutting Most of Workforce >FNCHJanuary 24, 2023 | finance.yahoo.comFinch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other AssetsNovember 11, 2022 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Kezar Life Sciences (KZR), RVL Pharmaceuticals (RVLP)November 11, 2022 | finance.yahoo.comFinch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial ResultsNovember 9, 2022 | finance.yahoo.comFinch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx ConferenceOctober 24, 2022 | finance.yahoo.comFinch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile InfectionOctober 1, 2022 | seekingalpha.comFNCH Finch Therapeutics Group, Inc.September 1, 2022 | finance.yahoo.comAfter Takeda ends collaboration, microbiome startup Finch Therapeutics cuts 50 jobsSeptember 1, 2022 | markets.businessinsider.comFinch Therapeutics To Reduce Workforce - Quick FactsSee More Headlines Receive FNCH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address FNCH Company Calendar Last Earnings8/10/2023Today9/29/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FNCH CUSIPN/A CIK1733257 Webwww.finchtherapeutics.com Phone617-229-6499FaxN/AEmployees18Year FoundedN/APrice Target and Rating Average Stock Price Forecast$210.00 High Stock Price Forecast$210.00 Low Stock Price Forecast$210.00 Forecasted Upside/Downside+4,017.6%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($86.6130) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-114,650,000.00 Net Margins-25,084.36% Pretax Margin-56,019.37% Return on Equity-115.37% Return on Assets-64.42% Debt Debt-to-Equity RatioN/A Current Ratio3.81 Quick Ratio3.81 Sales & Book Value Annual Sales$860,000.00 Price / Sales9.49 Cash FlowN/A Price / Cash FlowN/A Book Value$60.01 per share Price / Book0.08Miscellaneous Outstanding Shares1,600,000Free Float884,000Market Cap$8.16 million OptionableNot Optionable Beta0.17 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Matthew P. Blischak J.D.Chief Exec. OfficerMr. Lance Thibault CPA (Age 57)CPA, Chief Financial Officer Mr. James S. Sigler MBA (Age 62)Exec. VP of CMC Key CompetitorsBioCardiaNASDAQ:BCDAAvalon GloboCareNASDAQ:ALBTCreative Medical TechnologyNASDAQ:CELZTitan PharmaceuticalsNASDAQ:TTNPInhibikase TherapeuticsNYSE:IKTView All CompetitorsInsiders & InstitutionsBaupost Group LLC MASold 1,951,712 shares on 8/11/2023Ownership: 4.206%Lake Street Advisors Group LLCSold 717,930 shares on 8/10/2023Ownership: 1.323%Marc BlausteinSold 153 sharesTotal: $1,744.20 ($11.40/share)Marc BlausteinSold 121 sharesTotal: $5,045.70 ($41.70/share)View All Insider TransactionsView All Institutional Transactions FNCH Stock - Frequently Asked Questions What is Finch Therapeutics Group's stock price forecast for 2023? 0 brokers have issued 12-month target prices for Finch Therapeutics Group's stock. Their FNCH share price forecasts range from $210.00 to $210.00. On average, they expect the company's share price to reach $210.00 in the next twelve months. This suggests a possible upside of 4,017.6% from the stock's current price. View analysts price targets for FNCH or view top-rated stocks among Wall Street analysts. How have FNCH shares performed in 2023? Finch Therapeutics Group's stock was trading at $14.40 on January 1st, 2023. Since then, FNCH stock has decreased by 64.6% and is now trading at $5.10. View the best growth stocks for 2023 here. Are investors shorting Finch Therapeutics Group? Finch Therapeutics Group saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 28,500 shares, an increase of 27.2% from the August 31st total of 22,400 shares. Based on an average daily trading volume, of 10,500 shares, the short-interest ratio is presently 2.7 days. Currently, 5.1% of the company's stock are sold short. View Finch Therapeutics Group's Short Interest. When is Finch Therapeutics Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our FNCH earnings forecast. How were Finch Therapeutics Group's earnings last quarter? Finch Therapeutics Group, Inc. (NASDAQ:FNCH) posted its earnings results on Thursday, August, 10th. The company reported ($4.33) earnings per share for the quarter, topping the consensus estimate of ($4.51) by $0.18. Finch Therapeutics Group had a negative trailing twelve-month return on equity of 115.37% and a negative net margin of 25,084.36%. When did Finch Therapeutics Group's stock split? Finch Therapeutics Group's stock reverse split on Monday, June 12th 2023. The 1-30 reverse split was announced on Monday, June 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Finch Therapeutics Group IPO? (FNCH) raised $101 million in an IPO on Friday, March 19th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO. What is Finch Therapeutics Group's stock symbol? Finch Therapeutics Group trades on the NASDAQ under the ticker symbol "FNCH." How do I buy shares of Finch Therapeutics Group? Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Finch Therapeutics Group's stock price today? One share of FNCH stock can currently be purchased for approximately $5.10. How much money does Finch Therapeutics Group make? Finch Therapeutics Group (NASDAQ:FNCH) has a market capitalization of $8.16 million and generates $860,000.00 in revenue each year. The company earns $-114,650,000.00 in net income (profit) each year or ($86.6130) on an earnings per share basis. How can I contact Finch Therapeutics Group? The official website for the company is www.finchtherapeutics.com. The company can be reached via phone at 617-229-6499 or via email at ir@finchtherapeutics.com. This page (NASDAQ:FNCH) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Finch Therapeutics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.